[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30 Disclosures
[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary / 2024-12-30 Disclosures
[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary / 2024-12-30 Disclosures
[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30 Disclosures
[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Capital Increase by Subsidiary / 2024-12-30 Disclosures
[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in the US / 2024-12-27 Disclosures
[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Debt Guarantee for Others / 2024-12-26 Disclosures
![[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환한화오션.jpg)
![[Disclosure] Hanwha Systems (272210) – (Correction) Sales / Supply Contract / 2024-12-30](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환한화시스템.jpg)
![[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in the US / 2024-12-27](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환셀트리온.jpg)